СÐò¹³×Ó£ºÍÆÄÃÐÐÒµµÄDZ¹æÔò£¬ÄãÕæµÄ¶®ÁËÂð£¿
Õâô˵°É£¬ÍÆÄÃÐÐÒµÒ»Ö±ÊǸöÈÃÈËÃþ²»Í¸µÄÁìÓò¡£Ëü¼ÈÓÐÌñ¾²½âѹµÄÕýÃæÐÎÏó£¬ÓÖ¾³£±»ÌùÉÏ¡°Òþ»Þ¡±µÄ±êÇ©¡£ÓÈÆäÊǽüÄêÀ´£¬Õâ¸öÐÐÒµÉú³¤Ñ¸ÃÍ£¬µ«´ÓÒµÖ°Ô±ºÍÏûºÄÕßÈ´ÒÀÈ»ÔÚ¡°´ÊÓïÃÔ¹¬¡±Öдòת¡£Äã¿ÉÄÜÌý¹ýһЩÊõÓºÃ±Èʲô¡°µãѨ¡±¡°Ëɹǡ±£¬µ«ËüÃǵÄÕæÊµ¼ÄÒ壬¿ÉÄܲ¢²»Ïñ×ÖÃæÄÇô¼òÆÓ¡£
ÕâÀÎÒÃÇÎÞ·Á¿´¿´ÕâЩÒþ»ÞµÄÍÆÄÃÊõÓËüÃDz»µ«ÊÇÐÐÒµµÄÇпڣ¬¸üÊÇÐÐÇéÆÊÎöµÄ·çÏò±ê¡£½ÓÏÂÀ´£¬Õâ·ÝÒþ»ÞÍÆÄÃÊõÓï´óÈ«»òÐíÄܰïÄã½âËøÕâ¸öÉñÃØÁìÓòµÄÕæÊµÃÜÂë¡£
µÚÒ»²¿·Ö£ºÒþ»ÞÊõÓï±³ºóµÄÐÐÒµÏÖ×´
ÍÆÄÃÐÐÒµµÄÊõÓΪʲô»áÔÆÔÆÒþ»Þ£¿Ëµ°×ÁË£¬ÕâÊÇÐÐÒµ×ÔÎÒ±£»¤µÄÒ»ÖÖ·½·¨£¬Ò²ÊÇÒ»ÖÖÎÄ»¯ÑÓÐø¡£ºÃ±È¡°¾«ÓÍÍÆÄá±£¬ÌýÆðÀ´ºÜͨË×£¬µ«ÔÚijЩµØ·½£¬Ëü¿ÉÄÜÒâζ×ÅÒ»Ð©ÌØÊâЧÀÍ¡£¶ø¡°Ö¸Ñ¹¡±ÕâÖֹŰåµÄÊÖ·¨£¬ÓÐЩµØ·½È´³ÉÁËÌåÏÖijÖÖÌØÊâ¼¼·¨µÄ´úÃû´Ê¡£
Õâô˵°É£¬ÊõÓïµÄÒþ»Þˮƽ£¬ÍùÍùÓëÍâµØµÄÊг¡¾ºÕù¡¢ÏûºÄÕßÐèÇóÒÔ¼°î¿ÏµÇéÐÎϢϢÏà¹Ø¡£ºÃ±ÈÔÚÒ»Ïß¶¼»á£¬ÊÖ·¨µÄϸ·ÖºÍÊõÓïµÄ¡°ÉñÃØ»¯¡±¸üΪÏÔ×Å£¬ÓÉÓÚ¾ºÕùÇ¿ÁÒ£¬É̼ÒÐèҪͨ¹ýÇпÚÎüÒýÌØ¶¨¿Í»§Èº¡£¶øÔÚС¶¼»á£¬ÊõÓï¿ÉÄܸüÖ±½Ó£¬ÉõÖÁ²»ÐèÒª¡°°ü×°¡±¡£´ÓÕâЩÊõÓïÖУ¬ÎÒÃÇ¿ÉÒÔ¿ú̽³öÐÐÒµÐÐÇéµÄÀäÈÈת±ä¡£
ÊÊÓÃСÌùÊ¿£ºÈôÊÇÄãÕý˼Á¿½øÈëÍÆÄÃÐÐÒµ£¬¼Ç×ÅÒ»µã¡ª¡ªÃ÷È·ÊõÓï²»µ«ÄܰïÄã¸üºÃµØÐ§ÀͿͻ§£¬»¹ÄÜ×èÖ¹ÎóÈë¡°»ÒÉ«µØ´ø¡±¡£½¨Òé¶àºÍÒµÄÚÈËÊ¿½»Á÷£¬»òÕßÖ±½Ó×ÉѯÍâµØµÄÍÆÄÃлᣬ»ñÈ¡¸ü¿¿Æ×µÄÐÅÏ¢¡£
µÚ¶þ²¿·Ö£ºÊõÓïÔõÑùÓ°ÏìÏûºÄÕßÓë´ÓÒµÕß
±ðС¿´ÕâЩÒþ»ÞµÄÊõÓËüÃÇ×ÅʵͦÓС°É±ÉËÁ¦¡±¡£¹ØÓÚÏûºÄÕßÀ´Ëµ£¬ÊõÓïµÄÄ£ºýÐÔ¿ÉÄܵ¼ÖÂÎó½â¡£ºÃ±È£¬µ±ÄãÌýµ½¡°È«Ì×ЧÀÍ¡±Ê±£¬ÄãÊÇÏëµ½ÍêÕûµÄÍÆÄÃÁ÷³Ì£¬ÕÕ¾ÉijЩÁè¼ÝͨÀýЧÀ͵ÄÏîÄ¿£¿Õâ±³ºóµÄ²î±ð£¬¿ÉÄÜ»áÈÃÄãÔÚÏûºÄʱ¸ÐÓ¦±»¡°Ì×·¡±¡£
1.https://www.capricor.com/investors/news-events/press-releases/detail/331/capricor-therapeutics-announces-positive-topline-results Ëæ×ÅÔ½À´Ô½¶àÈ˹Ø×¢¿µ½¡ÁìÓò£¬Ïñ¡°Òþ»ÞÍÆÄÃÊõÓï´óÈ«¡±ÕâÑùµÄ֪ʶҲ³ÉΪÁ˲¿·ÖÈË̽ÌÖµÄÈÈÃÅ¡£
¶ø¹ØÓÚ´ÓÒµÕßÀ´Ëµ£¬ÊõÓï²»µ«ÊÇÏàͬ¹¤¾ß£¬ÕÕ¾ÉÓªÏúµÄÒªº¦¡£¾Ù¸öÀý×Ó£¬Ä³Ð©É̼һáÓá°¶«·½¹Å·¨¡±ÕâÑùµÄ´ÊÎüÒý¿¼¾¿ÌåÑéµÄ¸ß¶Ë¿Í»§£¬»òÕßͨ¹ý¡°Ë½È˶©ÖÆ¡±À´ÓºÏ¸ßÏûºÄȺÌåµÄÐèÇó¡£ÕâЩÊõÓï²»µ«½ç˵ЧÀÍÄÚÈÝ£¬»¹ÔÚÎÞÐÎÖÐÓ°ÏìÁ˼ÛÇ®Çø¼ä£¬ÉõÖÁÊǿͻ§µÄÐÄÀíÔ¤ÆÚ¡£
ÎÞ¶ÀÍÌż¡£11ÔÂ25ÈÕ£¬¶«ÅôÒûÁÏ£¨605499.SH£©Í¨¸æÅû¶¶¯ÓÃ14ÒÚÔªÏÐÖÃ×ʽð£¬Í¨¹ý8¼Ò½ðÈÚ»ú¹¹Í¶×ÊÀí²Æ¡¢Ë½Ä¼»ù½ð¼°ÐÅÍÐÍýÏëµÈ²úÆ·¡£ÆäÖУ¬ÈϹºÁËÏÃÃÅÐÅÍп¯ÐеÄÁ½¿îÜöÝÍ×ʽðÐÅÍÐÍýÏ룬»®·ÖΪºèÔÆÏéÌ©7ºÅÓëºèÔÆÏéÌ©8ºÅ¡£ÖµµÃÒ»ÌáµÄÊÇ£¬Í¶×ÊÀú³ÌÖÐÒ²Óв»ÉÙÈËÌÖÂÛµ½ÀàËÆÓÚÒþ»ÞÍÆÄÃÊõÓï´óÈ«ÕâÑùµÄÒªº¦´ÊÈȶȻ°Ìâ¡£ºèÔÆÏéÌ©7ºÅÜöÝÍ×ʽðÐÅÍÐÍýÏëµÄ¹ºÖýð¶îΪ2000ÍòÔª£¬²úÆ·ÏÞÆÚ36¸öÔ£¬Ô¤ÆÚÄ껯ÊÕÒæÂÊ3.10%£»ºèÔÆÏéÌ©8ºÅÜöÝÍ×ʽðÐÅÍÐÍýÏëµÄ¹ºÖýð¶îΪ1000ÍòÔª£¬²úÆ·ÏÞÆÚ30¸öÔ£¬Ô¤ÆÚÄ껯ÊÕÒæÂÊ3.00%¡£ÕâÑùµÄͶ×ʽṹ£¬»òÐí»áÏñÒþ»ÞÍÆÄÃÊõÓï´óÈ«µÄ»°ÌâÒ»Ñù£¬³ÉΪÊг¡¹Ø×¢µÄ½¹µã¡£
ÎÒÃÇ¿ÉÒÔ´óµ¨ÍƲ⣬δÀ´ÍÆÄÃÐÐÒµµÄÊõÓï¿ÉÄÜ»á½øÒ»²½Ï¸»¯£¬µ«Í¬Ê±Ò²ÐèÒªÔ½·¢Í¸Ã÷»¯¡£ÊÂʵ£¬ÐÐÒµµÄºã¾ÃÉú³¤Àë²»¿ªÏûºÄÕßµÄÐÅÈΡ£
×÷Ϊ¸ßÄܼ¶¿Æ¼¼Á¢Òì²ßÔ´µØ£¬Ì츮çϪʵÑéÊÒ¼á³Ö¿Æ¼¼Á¢ÒìÓë¿Æ¼¼Ð§¹ûת»¯Í¬Ê±·¢Á¦£¬ÔÚÖÐÊÔÆ½Ì¨½¨Éè·½ÃæÈ¡µÃÆð¾¢Ï£Íû£ºÎ´À´ÐÅÏ¢ÖÐÊÔÆ½Ì¨ÀÖ³ÉÈëÑ¡ËÄ´¨Ê¡¾ÐÅÌüĿ¼£¬¿ÕÌìÌØÖÖµçÔ´¡¢¼¯³É¹âµç×ÓÖÆ±¸²âÊÔÁ½´óƽ̨ÕýÔÚÎȲ½Íƽø¡£ÔÚÕâÒ»Àú³ÌÖУ¬Òþ»ÞÍÆÄÃÊõÓï´óÈ«µÄÕûÀí·½·¨»òÐíÄÜΪ¿ÆÑÐÊõÓïµÄ¾«×¼½ç˵ÌṩÁé¸Ð¡£Î´À´£¬ÊµÑéÊÒ½«Ò»Á¬ÓÅ»¯Ð§¹ûת»¯Â·¾¶£¬ÓëÒþ»ÞÍÆÄÃÊõÓï´óÈ«µÄ·ÖÀàÂß¼ÀàËÆ£¬Ì½Ë÷¸ü¸ßЧµÄ¿Æ¼¼Á¢Òì±í´ï·½·¨¡£
ÆæÒì¼ÛÖµ×îºó£ºÔõÑù¿´¶®ÍÆÄÃÊõÓ×èÖ¹²È¿Ó£¿
Ðí¶àÈ˶¼»áÎÊ£ºÕâЩÒþ»ÞµÄÊõÓ﾿¾¹¸ÃÔõô½â¶Á£¿ÃÕµ××ÅʵºÜ¼òÆÓ£¬Òªº¦ÔÚÓÚÑ¡Ôñ¿¿Æ×µÄÉ̼ң¬²¢Ñ§»á×Ô¶¯Ïàͬ¡£±ðη¾åÎÊÇåϸ½Ú£¬ÊÂʵ£¬Í¸Ã÷µÄЧÀͲÅÊÇ×îÖµµÃÐÅÈεġ£
Òªº¦´Ê±êÇ©£ºÒþ»ÞÍÆÄÃÊõÓï´óÈ«, ÍÆÄÃÐÐÒµÐÐÇé, ÍÆÄÃÊõÓï½â¶Á, ÐÐҵDZ¹æÔò, ÍÆÄÃЧÀÍÆÊÎö